Workflow
Bacteriophage Therapy
icon
Search documents
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
Prnewswireยท 2025-08-12 20:05
Core Insights - Armata Pharmaceuticals announced positive topline results from the Phase 1b/2a diSArm trial for its therapeutic candidate AP-SA02, demonstrating efficacy in treating complicated S. aureus bacteremia [3][4] - The company entered into a secured credit agreement with Innoviva for $15 million, maturing in 2029, to support the development of AP-SA02 [4] - Financial results for Q2 2025 showed a loss from operations of approximately $6.8 million, a significant reduction from a loss of approximately $11.9 million in Q2 2024 [8][16] Financial Overview - Grant and award revenue for Q2 2025 was $2.2 million, compared to no grant revenue in Q2 2024 [6] - Research and development expenses decreased to approximately $6.4 million in Q2 2025 from approximately $8.5 million in Q2 2024 [7] - General and administrative expenses also decreased to approximately $2.6 million in Q2 2025 from approximately $3.4 million in Q2 2024 [8] Development Updates - The diSArm study met all primary endpoints for safety, tolerability, and clinical response, with AP-SA02 showing improved clinical outcomes compared to the best available antibiotic therapy [4] - Armata plans to hold an End of Phase 2 meeting with the FDA later this year to discuss the design of a pivotal trial for AP-SA02 [4] - The company received an additional $4.65 million in non-dilutive funding from the U.S. Department of Defense to support the diSArm study and FDA meeting preparations [4] Cash Position - As of June 30, 2025, Armata had approximately $4.3 million in unrestricted cash and cash equivalents, down from $9.3 million as of December 31, 2024 [9] - The company reported a net loss of $16.3 million for the six months ended June 30, 2025, compared to a net income of $9 million for the same period in 2024 [16]